Atossa Therapeutics Inc. has received Rare Pediatric Disease $(RPD)$ designation from the U.S. Food and Drug Administration (FDA) for its drug candidate (Z)-Endoxifen for the treatment of Duchenne Muscular Dystrophy (DMD). This regulatory milestone may qualify Atossa for a Priority Review Voucher upon future approval, which could be used for expedited FDA review of another application or sold to another company. The designation recognizes (Z)-Endoxifen's potential as a treatment for DMD, a severe childhood neuromuscular disease, and highlights its differentiated mechanism that does not target specific exon defects, potentially broadening its applicability among patients. No other organizations were mentioned as recipients of this regulatory designation.